Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Theodore Stephens

Internal Medicine Baltimore, MD Medical Doctor

NPI 1396842076 CMS profile 244629

1005 N Point Blvd, Suite 724, Baltimore, MD 21224

Open in the dashboard

General payments

$3,035

81 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Theodore Stephens of Baltimore, MD is reported in the CMS Open Payments database as having received $3,035 across 81 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $383 3
2023 General $125 1
2022 General $249 9
2021 General $343 20
2020 General $251 14
2019 General $1,683 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theodore Stephens
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Theodore Stephens were reported at $383. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Theodore Stephens Internal Medicine median Middle half National median
2019 $1,683 $159 $48–$570 $163
2020 $251 $119 $33–$402 $114
2021 $343 $135 $37–$521 $132
2022 $249 $141 $42–$496 $149
2023 $125 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $383 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $1,020 2 payments
  2. Novo Nordisk Inc $444 29 payments
  3. AstraZeneca Pharmaceuticals LP $296 11 payments
  4. Dexcom, Inc. $265 2 payments
  5. Abbott Laboratories $259 3 payments
  6. Sanofi-Aventis U.S. LLC $202 10 payments
  7. GlaxoSmithKline, LLC. $157 7 payments
  8. Merck Sharp & Dohme Corporation $95 6 payments
  9. Covidien LP $91 2 payments
  10. Amarin Pharma Inc. $59 3 payments
  11. Other $147 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,035 80 payments
  2. Consulting Fee $1,000 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $295 23 payments
  2. FARXIGA $278 10 payments
  3. FreeStyle Libre 3 $243 2 payments
  4. RYBELSUS $206 15 payments
  5. Tresiba $149 6 payments
  6. DEXCOM G7 GSS (161) $140 1 payment
  7. DEXCOM STELO GLUCOSE BIOSENSOR $140 1 payment
  8. Dexcom G6 Transmitter $125 1 payment
  9. SOLIQUA 100/33 $106 5 payments
  10. Situate $91 2 payments
  11. Other $871 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 102 drugs

Part D claims

4,939

Median for Internal Medicine: 777

Drug cost

$450,821

Median for Internal Medicine: $73,373

Branded share of claims

24.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 91 $75,779
Trulicity Dulaglutide Brand 48 $59,035
Eliquis Apixaban Brand 68 $53,282
Ozempic Semaglutide Brand 33 $43,166
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 65 $39,566
Jardiance Empagliflozin Brand 46 $38,690
Januvia Sitagliptin Phosphate Brand 28 $27,240
Victoza 3-Pak Liraglutide Brand 11 $18,047
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 16 $9,635
Tresiba Flextouch U-100 Insulin Degludec Brand 14 $7,906

The 10 drugs with the highest cost, of 102 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$104,744

Medicare's payments for the services billed

Medicare patients

281

Average age 75

Services billed

1,861

166 women, 115 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 39%
Chronic kidney disease 37%
Ischemic heart disease 25%
Depression 23%
Atrial fibrillation 15%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

81 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record